Study of the Anti-FGF23 Antibody, Burosumab, in Adults With XLH
A Phase 3b Open-label Study of the Anti-FGF23 Antibody, Burosumab (KRN23) in Adult Patients With X-linked Hypophosphatemia (XLH)
Sponsor: Kyowa Kirin Pharmaceutical Development Ltd
Listed as NCT03920072, this PHASE3 trial focuses on X-linked Hypophosphatemia and remains completed. Sponsored by Kyowa Kirin Pharmaceutical Development Ltd, it has been updated 9 times since 2019, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
9 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jun 2022 — Jul 2024 [monthly]
Completed PHASE3
Status: Active Not Recruiting → Completed
-
Oct 2021 — Jun 2022 [monthly]
Active Not Recruiting PHASE3
Status: Recruiting → Active Not Recruiting
-
Jan 2021 — Oct 2021 [monthly]
Recruiting PHASE3
▶ Show 4 earlier versions
-
Dec 2019 — Jan 2021 [monthly]
Recruiting PHASE3
-
Nov 2019 — Dec 2019 [monthly]
Recruiting PHASE3
-
Sep 2019 — Nov 2019 [monthly]
Recruiting PHASE3
-
May 2019 — Sep 2019 [monthly]
Recruiting PHASE3
First recorded
Mar 2019
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Kyowa Kirin Pharmaceutical Development Ltd
For direct contact, visit the study record on ClinicalTrials.gov .